ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
Dow Jones
37.815,92
-1,49%
Euro vs US Dollar
1,06642
-0,02%
Bitcoin
57.043,37
-5,87%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Invitae Corporation (NVTA)

  7. Invitae Corporation (NVTA) News

NVTA

Invitae (NVTA)

Invitae Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:NVTA
DatumZeitQuelleÜberschriftSymbolFirma
06/03/202414h31Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
06/02/202423h07Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
30/01/202413h00PR Newswire (US)Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsNYSE:NVTAInvitae Corporation
29/01/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:NVTAInvitae Corporation
24/01/202422h34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:NVTAInvitae Corporation
22/01/202413h05Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
22/01/202413h00PR Newswire (US)Invitae Completes Sale of Reproductive Health Assets to NateraNYSE:NVTAInvitae Corporation
18/01/202422h10Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
22/12/202303h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
22/12/202303h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
14/12/202322h29Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
13/12/202322h07PR Newswire (US)Invitae Divests Ciitizen Health Data Platform and Implements Further Cost CutsNYSE:NVTAInvitae Corporation
11/12/202322h41Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
17/11/202322h48Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
15/11/202322h22Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
15/11/202301h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
15/11/202301h55Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
08/11/202322h36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NVTAInvitae Corporation
08/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
08/11/202322h01PR Newswire (US)Invitae Reports Third Quarter 2023 Financial ResultsNYSE:NVTAInvitae Corporation
06/11/202322h00PR Newswire (US)Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research PartnershipsNYSE:NVTAInvitae Corporation
01/11/202311h59PR Newswire (US)Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023NYSE:NVTAInvitae Corporation
25/10/202317h00PR Newswire (US)Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive ResultsNYSE:NVTAInvitae Corporation
21/10/202300h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
19/10/202322h38Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
19/10/202322h30PR Newswire (US)Invitae Appoints Dr. David Sholehvar as Chief Operating OfficerNYSE:NVTAInvitae Corporation
12/10/202322h15PR Newswire (US)Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast CancerNYSE:NVTAInvitae Corporation
10/10/202322h30PR Newswire (US)Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical GenomicsNYSE:NVTAInvitae Corporation
03/10/202318h07PR Newswire (US)Invitae's Common Hereditary Cancers Panel Receives FDA Market AuthorizationNYSE:NVTAInvitae Corporation
03/10/202303h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
 Showing the most relevant articles for your search:NYSE:NVTA

Kürzlich von Ihnen besucht

PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
TG
D7G
Nel ASA
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AAPL
Apple
TG
MBG
MercedesBenz
AMEX
XLV
Health Care Select Sector
DBI
DAX
DAX
TG
DBK
Deutsche Bank
TG
LHA
Deutsche Lufthansa
TG
NOV
Novo Nordisk
NASDAQ
NVDA
NVIDIA
CCOM
US100
US Tech 100
TG
BAS
BASF
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten